Report ID: SQMIG35I2209
Report ID:
SQMIG35I2209 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
89 |
Figures:
76
Evotec and the Crohn's & Colitis Foundation joined forces in January 2024 to research and develop novel treatments for inflammatory bowel disease (IBD). As part of this collaboration, both businesses will leverage Evotec's extensive research and development (R&D) infrastructure to progress the development of two novel therapeutic targets, fibrosis and compromised intestinal barrier function.
Simcyp Biopharmaceutics software, which Certara unveiled in November 2023, is designed to make the process of developing novel and generic medication formulations more efficient. The Simcyp Biopharmaceutics program is intended to help scientists, formulationists, and biopharmaceuticists formulate complicated, innovative, and generic small molecule medications efficiently and economically.
A cloud-native SaaS platform called Signals Research Suite was introduced by Revvity, Inc. in December 2023 with the goal of accelerating the discovery of drugs and materials. It facilitates scientific cooperation between researchers in different R&D fields, such as medicine development and specialized chemical material creation. The new solution is a strong solution that covers the full drug development process, from early research and in vitro testing and safety to early development and specialty chemical new product development. It includes the VitroVivo, Inventa, and Revvity Signals Notebook tools.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2209